NCT00215501已完成1 期
A Phase I Trial of Capecitabine or Continuous Infusion 5-Fluorouracil in Combination With Weekly Irinotecan and Cisplatin in Patients With Advanced Solid Tumor Malignancies
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 54
- 试验地点
- 3
- 主要终点
- To determine dose limiting toxicity, maximum tolerated dose and recommended Phase II dose of both capecitabine and 5-fluorouracil in this patient population.
研究概览
简要总结
The purpose of this study is to test the safety of irinotecan and cisplatin in combination with either capecitabine or continuous infusion 5-fluorouracil and to see what effects (good and bad) these have on patients with unresectable, advanced solid tumors.
详细描述
- This is a Phase I dose escalation study. The dose of drug the patient receives will be assigned based upon when they enter the study. Since we are looking for the highest dose of capecitabine or 5-fluorouracil that can be given safely in combination with cisplatin and irinotecan, not everyone who participates in this study will be receiving the same amount of the drug.
- There are four parts to this study: 1)Choice of treatment, 2)Evaluation, 3)Chemotherapy and 4)Follow-up.
- The patient and the patient's doctor will decide which form of chemotherapy is best for the patient, either pill form or continuous infusion. Chemotherapy pills (capecitabine) are given twice per day for 14 days is a row every 3 weeks. Continuous infusion (5-fluorouracil) is given through a pump 24 hours a day for 14 days every 3 weeks.
- Prior to initiation to therapy the extent of the patients cancer will be evaluated. This includes a CT scan, chest x-ray, EKG and bloodwork.
- Patient's will receive chemotherapy for 2 weeks followed by a one week break. This will constitute one cycle. The medications cisplatin and irinotecan will be given intravenously on the 1st and 8th day of each cycle. Following the rest period the next cycle of chemotherapy begins.
- Following 2 cycles of chemotherapy, the patients cancer will be re-evaluated. A CT scan and bloodwork will be obtained and will be compared to the previous studies. Treatment will resume if the cancer is the same size or smaller than before and the patient is tolerating the chemotherapy well. The cancer will be re-evaluated every 2 cycles of chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed solid tumor malignancy
- •18 years of age or older
- •Two prior chemotherapy regimens for metastatic disease. Prior chemotherapy must have been completed at least 3 weeks prior to initiation of this protocol.
- •ECOG performance status of 0,1 or 2
- •Neutrophils greater or equal to 1,500/ul
- •Platelets greater or equal to 100,000/ul
- •Serum bilirubin less or equal to 1.5 mg/dl
- •Creatinine clearance greater than 50 ml/min
- •AST or SGOT less or equl to 3x ULN
- •Prior radiotherapy is allowable, provided at least 4 weeks have elapsed and the patient has recovered from all therapy related side effects.
排除标准
- •Life expectancy of less than 3 months
- •Clinically significant cardiac disease or myocardial infarction within past 6 months
- •Suspicion or documentation of CNS metastases or carcinomatous meningitis
- •Psychiatric disability judged by the investigator to be clinically significant, precluding informed consent
- •Known existing coagulopathy and/or requires therapeutic anticoagulants
- •Uncontrolled diarrhea
- •Peripheral neuropathy
- •Major surgery within 3 weeks of the state of the study treatment without complete recovery
- •Serious, uncontrolled, concurrent infection
- •Lack of physical integrity of upper gastrointestinal tract or malabsorption syndrome
- •Prior severe reaction to fluoropyrimidine, irinotecan or cisplatin
- •Known interstitial pulmonary fibrosis
- •Known Gilbert's disease
- •Uncontrolled diabetes mellitus
- •Organ allograft(s) on immunosuppressive therapy
- •Pregnant or lactating women
- •Patients taking valproic acid
研究组 & 干预措施
Group A
Experimental
Oral capecitabine
干预措施: Capecitabine (Drug)
Group A
Experimental
Oral capecitabine
干预措施: Irinotecan (Drug)
Group A
Experimental
Oral capecitabine
干预措施: Cisplatin (Drug)
Group B
Experimental
5-fluorouracil
干预措施: 5-Fluorouracil (5-FU) (Drug)
Group B
Experimental
5-fluorouracil
干预措施: Irinotecan (Drug)
Group B
Experimental
5-fluorouracil
干预措施: Cisplatin (Drug)
结局指标
主要结局
To determine dose limiting toxicity, maximum tolerated dose and recommended Phase II dose of both capecitabine and 5-fluorouracil in this patient population.
时间窗: 2 years
次要结局
- To make a preliminary assessment of the anti-tumor activity of these combinations.(2 years)
研究者
Peter C. Enzinger, MD
Principal Investigator
Dana-Farber Cancer Institute
研究点 (3)
Loading locations...
相似试验
Unknown
1 期
A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal CancerMetastatic CancerColorectal AdenocarcinomaColorectal CancerNCT04380103Chinese Academy of Medical Sciences106
终止
2 期
Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage TreatmentMetastatic Colorectal CancerNCT00717990University Hospital of Crete15
终止
2 期
Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine CarcinomaNeuroendocrine CarcinomaNCT03168594Peking University66
已完成
2 期
Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer PatientsMetastatic Colorectal CancerNCT00875771Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)80
终止
2 期
Study of Irinotecan & Capecitabine in Metastatic Colorectal CancerSecondaryDrug Therapy, CombinationColorectal NeoplasmsNCT00506168National Cancer Center, Korea37